A Phase II Trial of BIBF1120 in Patients with Advanced FGFR3 Mutated, FGFR3 Overexpressed, or FGFR3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and Renal Pelvis and Who Have Failed Platinum-Based Chemotherapy (I)

2014-02-012024-05-17https://scholars.lib.ntu.edu.tw/handle/123456789/678387A Phase II Trial of BIBF1120 in Patients with Advanced FGFR3 Mutated, FGFR3 Overexpressed, or FGFR3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and Renal Pelvis and Who Have Failed Platinum-Based Chemotherapy (I)